Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Corcept Therapeutics’ SEC documents can feel like decoding a clinical protocol. The company’s filings overflow with data on glucocorticoid receptor trials, hypercortisolism patient outcomes, and R&D spend that shifts with every Phase 3 update—details investors can’t ignore yet rarely have time to dissect. Stock Titan’s AI turns these dense pages into clear takeaways, so “Corcept Therapeutics SEC filings explained simply” is more than a promise; it’s a deliverable.
Need the latest “Corcept Therapeutics quarterly earnings report 10-Q filing” or want to see how rising trial costs flow through cash burn? Our platform captures each 10-Q the moment it posts to EDGAR, then highlights revenue from Korlym, pipeline expense, and guidance shifts. The full annual report—think “Corcept Therapeutics annual report 10-K simplified”—is automatically condensed, surfacing FDA risk factors and licensing obligations in minutes. Prefer narrative? The earnings report filing analysis module answers searches like “Corcept Therapeutics earnings report filing analysis.” Sudden study read-outs? An “Corcept Therapeutics 8-K material events explained” panel pinpoints what changed and why. All of this exemplifies understanding Corcept Therapeutics SEC documents with AI.
Monitoring management sentiment? Real-time dashboards surface every “Corcept Therapeutics insider trading Form 4 transactions.” You’ll also find the exact phrase “Corcept Therapeutics Form 4 insider transactions real-time” already filtered by officer, option exercise, and date. Proxy statements reveal leadership incentives for anyone researching “Corcept Therapeutics proxy statement executive compensation.” Whether you’re tracking catalysts, benchmarking R&D efficiency, or following “Corcept Therapeutics executive stock transactions Form 4,” our AI-powered summaries, smart search, and export tools put the entire universe of Corcept Therapeutics filings within easy reach.
Corcept Therapeutics (CORT) – Form 4 insider activity
Sean Maduck, President of Corcept Endocrinology, exercised low-priced options and immediately sold the underlying shares pursuant to a 10b5-1 plan:
- 17 Jul 2025: Exercised 4,315 options at $5.05; sold 4,315 shares at a weighted-avg $73.4771.
- 18 Jul 2025: Exercised 473 options at $5.05; sold 473 shares at $73.4404.
Total shares sold: 4,788; gross proceeds ≈ $351k; per-share spread ≈ $68.4.
Post-trade holdings: 17,705 shares direct; 99,693 shares indirect (89,693 trust + 10,000 LLC); 56,993 vested options; 1,877 unvested RSAs.
The divestiture equals ~4 % of Maduck’s reported equity exposure and was pre-scheduled, suggesting limited informational content for the broader CORT investment thesis.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
